InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | 2026-04-07 | Bertolini Mark T | Director & Chief Executive Officer | Purchase | 1.00M | $11.92 | $11.92M | 10.20M | View ↗ | |
| 2026-03-02 | 2026-03-04 | Liang Janet | President, Oscar Insurance | Sale | 7,453 | $13.39 | $100K | 271.5K | View ↗ | |
| 2026-03-02 | 2026-03-04 | Baltrus Victoria | Chief Accounting Officer | Sale | 4,638 | $13.39 | $62K | 216.1K | View ↗ | |
| 2026-03-02 | 2026-03-04 | McAnaney Adam | Chief Legal Officer | Sale | 18.7K | $13.39 | $251K | 228.0K | View ↗ | |
| 2026-03-02 | 2026-03-04 | Schlosser Mario | Director & President of Technology & CTO | Sale | 24.3K | $13.39 | $326K | 515.0K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Premium | $11.47B+27.9% | $8.97B+57.8% | $5.69B+46.9% | $3.87B | — |
| Investment income | $202.9M+9.3% | $185.7M+19.5% | $155.4M+463.3% | $27.6M | — |
| Other revenues | $28.6M+39.0% | $20.6M-3.6% | $21.4M | — | — |
| Total revenue | $11.70B+27.5% | $9.18B+56.5% | $5.86B+47.9% | $3.96B+115.6% | $1.84B |
| Medical | $10.02B+36.6% | $7.33B+58.0% | $4.64B+41.5% | $3.28B | — |
| Selling, general, and administrative | $2.05B+16.8% | $1.76B+23.1% | $1.43B+13.4% | $1.26B | — |
| Depreciation and amortization | $28.9M-10.1% | $32.1M+4.7% | $30.7M+100.8% | $15.3M | — |
| Total operating expenses | $12.10B+32.6% | $9.12B+49.6% | $6.10B+33.9% | $4.55B+91.1% | $2.38B |
| Earnings (loss) from operations | -$396.4M-792.1% | $57.3M+124.3% | -$235.6M+60.1% | -$589.9M | — |
| Interest expense | $17.6M-25.8% | $23.7M-3.5% | $24.6M+8.8% | $22.6M+379.3% | $4.7M |
| Other expenses | $23.3M+22127.6% | $105K-98.5% | $7.1M | — | — |
| Earnings (loss) before income taxes | -$437.3M-1408.3% | $33.4M+112.5% | -$267.3M+56.2% | -$610.1M | — |
| Income tax expense | $5.6M-23.3% | $7.3M+121.8% | $3.3M | — | — |
| Net income (loss) | -$442.9M-1795.6% | $26.1M+109.7% | -$270.6M+55.6% | -$609.6M | — |
| Less: Net income attributable to noncontrolling interests | $248K-64.0% | $689K+414.2% | $134K | — | — |
| Net income (loss) attributable to Oscar Health, Inc. | -$443.2M-1842.5% | $25.4M+109.4% | -$270.7M+55.3% | -$606.3M | — |
| Basic (in dollars per share) | -$2K-1636.4% | $110+109.0% | -$1K+57.2% | -$3K | — |
| Diluted (in dollars per share) | -$2K-1790.0% | $100+108.2% | -$1K+57.2% | -$3K | — |
| Basic (in shares) | $262.39B+9.2% | $240.39B+8.5% | $221.66B+4.3% | $212.47B | — |
| Diluted (in shares) | $262.39B-1.3% | $265.85B+19.9% | $221.66B+4.3% | $212.47B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
This Fund Sold Out of Klaviyo Before a Brutal 32% Post-Earnings Drop
Oscar Health, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
MURGY vs. OSCR: Which Stock Is the Better Value Option?
Oscar Health (OSCR) Is Up 10.7% After Record Q1 2026 Profitability And Reaffirmed Guidance - Has The Bull Case Changed?